Navigation Links
Adalimumab is a promising therapy for children with Crohn's disease
Date:8/6/2012

Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

Steroids are commonly used in Crohn's disease, but can stunt growth and delay puberty. Incidence of this disease, which causes intestinal inflammation, is on the rise in children.

This study is the largest double-blind study of an anti-TNF agent in children with Crohn's disease. It found that more than 80 percent of children with moderate to severe Crohn's disease responded to adalimumab within a month (response was defined as a decrease in Pediatric Crohn's Disease Activity Index ≥ 15 points from baseline). By six months, approximately 34 percent of patients were in clinical remission, and after a year, 28.4 percent were in remission.

The promising results of treatment with adalimumab are extremely encouraging, especially in this clinically challenging population resistant to conventional therapy. The goal of treatment is not only to induce and maintain clinical remission, but also to restore and preserve normal growth and pubertal development in these children.

Researchers studied 192 patients, ages 6 to 17 years, across 45 sites in Canada, Europe and the U.S. between April 2007 and May 2010. Depending on their body weight, patients were assigned to either a high-dose group, which received 40 mg of adalimumab every other week or 20 mg of adalimumab every other week. Patients assigned to a low-dose group either received 20 mg of adalimumab every other week or 10 mg of adalimumab every other week, again depending on their body weight. More children that received high than low dose were in remission at week 26, but the difference between dose groups was not statistically significant.


'/>"/>

Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Page: 1

Related medicine news :

1. Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
2. New study identifies promising, achievable solutions to Nigerias childhood mortality crisis
3. Screening for breast cancer without X-rays: Lasers and sound merge in promising diagnostic technique
4. Stem Cell Study Shows Promising Results Against Heart Failure
5. Researchers make promising discovery in pursuit of effective lymphoma treatments
6. Diabetes drug could be a promising therapy for traumatic brain injury
7. Leukemia inhibitory factor may be a promising target against pancreatic cancer
8. Zebrafish reveal promising mechanism for healing spinal cord injury
9. Research identifies a promising new therapeutic target for aggressive breast cancer
10. Spice ingredient in curry emerges as promising basis for an Alzheimers disease medicine
11. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... Ogawa World USA ... its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D combines the ... each massage with a customized user profile and specialized massage program, each user has ...
(Date:5/3/2016)... ... 03, 2016 , ... Octo Consulting Group, Inc. ... services to the federal government, has been awarded a $9.9 million Task Order ... contract in support of the U.S. Army Program Executive Office for Enterprise Information ...
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... Branches, ... both its Grow & Climb children and youth programs in South Miami. Macy’s is ... years. , The Grow Program provides afterschool tutoring, mentoring, enrichment and academic support ...
(Date:5/3/2016)... ... , ... LunchSkins is changing the future of ocean plastic pollution ... away plastic baggies. The mission-driven bags give back to global leaders in the fight ... mission is all about reducing global plastic waste and we’ve teamed up with ...
(Date:5/3/2016)... ... May 03, 2016 , ... The ... issued by the Office of the National Coordinator for Health IT (ONC) with ... action when necessary, including suspending and terminating certifications issued to Complete EHRs and ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... 2016 TapImmune,Inc. (TPIV), a ... and gene-based immunotherapeutics and vaccines for the treatment of cancer ... the 3rd Annual Growth Capital Expo to be ... at Caesars Palace in Las Vegas, Nevada.  The Company ... 4 th by Dr. John N. Bonfiglio ...
Breaking Medicine Technology: